ACURA PHARMACEUTICALS, INC Form 8-K	
March 02, 2012	
UNITED STATES	
SECURITIES AND EXCHANGE COMMISSION	
WASHINGTON, D. C. 20549	
FORM 8-K	
CURRENT REPORT	
Pursuant to Section 13 or 15(d) of the	
Securities Exchange Act Of 1934	
March 2, 2012	
Date of Report (Date of earliest event reported)	
ACURA PHARMACEUTICALS, INC.	
(Exact Name of Registrant as Specified in Charter)	
State of New York (State of Other Jurisdiction of Incorporation)  1-10113 (Commission File Number)	11-0853640 (I.R.S. Employer Identification Number)
616 N. North Court, Suite 120	
Palatine, Illinois 60067	

(Address of principal executive offices) (Zip Code)

#### (847) 705-7709

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

"Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

"Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a-12)

"Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR240.14d-2(b))

"Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c))

### **Item 8.01 Other Events**

On March 2, 2012 we issued a press release providing an update on our Nexafed<sup>TM</sup> product in development. A copy of our press release is being filed as Exhibit 99.1 hereto and is incorporated herein by reference.

### **Item 9.01 Financial Statements and Exhibits**

Exhibit Number Description

99.1 Press Release dated March 2, 2012

### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

### ACURA PHARMACEUTICALS, INC.

By:/s/ Peter A. Clemens
Peter A. Clemens
Senior Vice President & Chief Financial Officer

Date: March 2, 2012

# **Exhibit Index**

Exhibit Number Description

99.1 Press Release dated March 2, 2012